Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2008

View Archived Issues

Repros reports results from two studies of Proellex

Novel cancer therapeutics described in recent patent literature

MMRC initiates phase I/II study of elotuzumab in combination with Velcade

AGI presents an update on the ARDIS phase III program for Rezular in IBS-D

Lilly pays Galapagos EUR 1 million milestone payment under osteoporosis collaboration

Neuren completes recruitment and dosing in phase III trial of Glypromate

sanofi-aventis terminates development and commercialization agreement with Taiho for S-1

Biocon and Abraxis launch Abraxane in India for breast cancer

New treatment option for HIV infection disclosed in recent Genzyme patent

Recent Merck patent divulges new agents for bone disorders

Genentech reports on preclinical profile of MetMAb in pancreatic cancer models

Allos initiates phase II PDX study in transitional cell carcinoma of the bladder

Ambrilia starts phase I/II program of novel goserelin formulation in prostate cancer

BioCancell requests to begin phase I BC-819 trial in pancreatic cancer

Intranasal administration of testosterone shows benefit against depressive-like behavior

Curis selects Hsp90 inhibitor CUDC-305 as development candidate

MI-63 plus cisplatin effective combination against cisplatin-resistant head and neck cancer

Exelixis commences phase III XL-184 trial in medullary thyroid cancer

Vascular disrupting agent ASA-404 shows benefit in mouse model of head and neck cancer

Roche offers to acquire all outstanding shares of Genentech

Targacept begins phase IIb TC-5214 trial in major depressive disorder

AlphaVax initiates studies of prototype chlamydia vaccine

CSL Behring submits BLA to FDA for human fibrinogen concentrate for congenital bleeding

BMP Sunstone signs letter of intent to acquire Shengda for approximately USD 4.4 million

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...